Celldex Therapeutics Inc. (NASDAQ:CLDX) shares traded down 4% during mid-day trading on Tuesday . The company traded as low as $4.51 and last traded at $4.52, with a volume of 875,303 shares trading hands. The stock had previously closed at $4.71.

A number of research analysts recently issued reports on the company. Cowen and Company reiterated an “outperform” rating and issued a $12.00 target price on shares of Celldex Therapeutics in a report on Tuesday, April 19th. Wedbush reiterated a “neutral” rating and issued a $3.00 target price on shares of Celldex Therapeutics in a report on Friday, May 6th. Roth Capital reiterated a “buy” rating and issued a $7.00 target price on shares of Celldex Therapeutics in a report on Tuesday, April 19th. Finally, Jefferies Group reiterated a “hold” rating and issued a $4.00 target price on shares of Celldex Therapeutics in a report on Friday, May 6th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $14.11.

The stock’s market capitalization is $461.11 million. The firm’s 50 day moving average is $4.49 and its 200-day moving average is $5.71.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting analysts’ consensus estimates of ($0.35). The firm had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.06 million. The company’s quarterly revenue was up 160.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.33) earnings per share. On average, analysts anticipate that Celldex Therapeutics Inc. will post ($1.36) earnings per share for the current fiscal year.

A number of hedge funds recently made changes to their positions in the stock. TSP Capital Management Group LLC increased its stake in shares of Celldex Therapeutics by 0.8% in the fourth quarter. TSP Capital Management Group LLC now owns 831,648 shares of the biopharmaceutical company’s stock valued at $13,040,000 after buying an additional 6,967 shares in the last quarter. Bedell Frazier Investment Counseling LLC increased its stake in shares of Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock valued at $1,023,000 after buying an additional 5,411 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock valued at $1,469,000 after buying an additional 9,072 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock valued at $1,700,000 after buying an additional 5,110 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Celldex Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 182,509 shares of the biopharmaceutical company’s stock valued at $2,862,000 after buying an additional 2,946 shares in the last quarter.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.